TG THERAPEUTICS, INC. (TGTX) FY2026 YTD Q2 P&L / Income Statement

TG THERAPEUTICS, INC. (TGTX) FY2026 YTD Q2 P&L / Income Statement

Income statement for 2026-01-01 through 2026-06-30. View: Product and service. Revenue uses this breakdown; costs and expenses retain the consolidated categories.

Revenue

445,253,000 US dollars

Cost of revenue

74,704,000 US dollars

Gross profit (calculated)

370,549,000 US dollars

Operating expenses (calculated)

314,080,000 US dollars

Operating income

56,469,000 US dollars

Total other expense

negative 25,872,000 US dollars

Net income before taxes

30,597,000 US dollars

Income tax expense

3,039,000 US dollars

Net income

27,558,000 US dollars

Product

437,102,000 US dollars

License Revenue

8,151,000 US dollars

Other research and development

130,788,000 US dollars

Stock-based compensation

12,945,000 US dollars

Other selling, general and administrative

135,467,000 US dollars

Stock-based compensation

34,880,000 US dollars

Chart connections

• Revenue less cost of revenue equals gross profit; gross profit less operating expenses equals operating income.
• Operating income plus other income or expense equals income before tax. Income before tax less income tax expense or benefit equals net income.